Topical agents for oral cancer chemoprevention: A systematic review of the literature

Publication date: April 2017
Source:Oral Oncology, Volume 67
Author(s): Lucy Chau, Justin T. Jabara, Wanda Lai, Peter F. Svider, Blake M. Warner, Ho-Sheng Lin, S. Naweed Raza, Andrew M. Fribley
Objectives/hypothesisWe review the use of topical chemoprevention agents in patients with oral potentially malignant disorders (PMD).MethodsA systematic review of studies on topical chemoprevention agents for oral PMD from 1946 to November 2016 was conducted using the MEDLINE database, Embase, and Cochrane Library. Data were extracted and analyzed from selected studies including study type, sample size, demographics, treatment length, response rate, follow-up time, adverse effects, and recurrence.ResultsOf 108 studies, twenty-four, representing 679 cases met the inclusion criteria. The clinical lesions evaluated included oral leukoplakia, erythroplakia (OEL), verrucous hyperplasia (OVH), oral lichen planus, larynx squamous cell carcinoma, and oral squamous cell carcinoma (OSCC). The mean complete response rate for topical retinoid therapy was 32%. The mean complete response rate for 1% bleomycin therapy and 0.5% bleomycin was 40.2% and 25%, respectively. The complete response rate of OVH, OEL, and OSCC to photodynamic therapy ranged from 66.7% to 100%.ConclusionThere are a paucity of data examining topical treatment of oral PMDs. However, the use of topical agents among patients with oral lesions may be a viable complement or even alternative to traditional surgery, radiation, or systemic chemotherapy, with the advantage of reducing systemic side effects and sparing important anatomic structures. This study of 679 cases represents the largest pooled sample size to date, and the preliminary studies in this systematic review provide support for further inquiry.



http://ift.tt/2lFeipq